C4 Therapeutics (CCCC) EBIAT (2019 - 2026)

C4 Therapeutics' EBIAT history runs 8 years deep, the most recent figure standing at -$25.1 million for Q1 2026.

• In Q1 2026, EBIAT rose 4.53% year-over-year to -$25.1 million; the TTM figure through Mar 2026 stood at -$103.8 million (down 0.51% YoY), while the FY2025 annual figure was -$105.0 million, changed 0.3% from the prior year.
• EBIAT was -$25.1 million for Q1 2026 at C4 Therapeutics, down from -$20.5 million in the prior quarter.
• In the past five years, EBIAT ranged from a high of -$17.7 million in Q2 2024 to a low of -$37.2 million in Q4 2022.
• Historically, EBIAT has averaged -$29.2 million across 5 years, with a median of -$28.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: EBIAT tumbled 137.36% in 2022, then soared 50.68% in 2024.
• A 5-year view of EBIAT shows it stood at -$37.2 million in 2022, then gained by 6.54% to -$34.8 million in 2023, then advanced by 0.52% to -$34.6 million in 2024, then soared by 40.73% to -$20.5 million in 2025, then retreated by 22.63% to -$25.1 million in 2026.
• The last three EBIAT figures came in at -$25.1 million (Q1 2026), -$20.5 million (Q4 2025), and -$32.2 million (Q3 2025), per Business Quant data.